This webinar brought together pharma, US payers, and global HTA bodies to investigate how real-world evidence (RWE) is being used to inform questions of drug value and effectiveness. We’ll explore best practices for determining drug pricing and value using RWE, what this means for your evidence generation strategy, and consider how we can solve the risk-sharing equation to bring the required treatments to patients who need them most – at an affordable rate!
You’ll learn how:
Head of US HEOR Strategy
Dr. Pamela Bradt
Chief Science Officer
Head of Real-World Evidence, Senior Director